17-42541189-A-G
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PM1PM5PP3_StrongPP5_Very_Strong
The NM_000263.4(NAGLU):c.1004A>G(p.Tyr335Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000682 in 1,613,046 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y335S) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000263.4 missense
Scores
Clinical Significance
Conservation
Publications
- mucopolysaccharidosis type 3BInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P, Orphanet, Myriad Women’s Health
- Charcot-Marie-Tooth disease axonal type 2VInheritance: AD Classification: SUPPORTIVE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000263.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| NAGLU | NM_000263.4 | MANE Select | c.1004A>G | p.Tyr335Cys | missense | Exon 5 of 6 | NP_000254.2 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| NAGLU | ENST00000225927.7 | TSL:1 MANE Select | c.1004A>G | p.Tyr335Cys | missense | Exon 5 of 6 | ENSP00000225927.1 | ||
| NAGLU | ENST00000592454.1 | TSL:2 | c.98A>G | p.Tyr33Cys | missense | Exon 1 of 2 | ENSP00000468665.1 | ||
| NAGLU | ENST00000591587.1 | TSL:5 | c.360-1839A>G | intron | N/A | ENSP00000467836.1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152158Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.00000399 AC: 1AN: 250372 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000685 AC: 10AN: 1460888Hom.: 0 Cov.: 32 AF XY: 0.0000110 AC XY: 8AN XY: 726798 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152158Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 74336 show subpopulations
ClinVar
Submissions by phenotype
Mucopolysaccharidosis, MPS-III-B Pathogenic:1Uncertain:1
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.
This variant is classified as Pathogenic. Evidence in support of pathogenic classification: Variant is present in gnomAD <0.01 for a recessive condition (v4: 11 heterozygote(s), 0 homozygote(s)); This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been classified as pathogenic by clinical laboratories in ClinVar and reported in the literature in homozygous and compound heterozygous individuals with mucopolysaccharidosis type IIIB (Sanfilippo B) or NAGLU-related features (PMID: 30070758, 16151907, 33763395); This variant has moderate functional evidence supporting abnormal protein function. This variant was shown to decrease NAGLU activity, compared to the wildtype, in CHO cells (PMID: 16151907); Another missense variant(s) comparable to the one identified in this case has moderate previous evidence for pathogenicity. p.(Tyr335Ser) has been classified as likely pathogenic by clinical laboratories in ClinVar and reported in the literature in an individual with MPS IIIB (PMID: 36468061); Missense variant predicted to be damaging by in silico tool(s) or highly conserved with a major amino acid change; Heterozygous variant detected in trans with a second PATHOGENIC heterozygous variant, NM_000263.4(NAGLU):c.889C>T; p.(Arg297*), in a recessive disease. Additional information: Variant is predicted to result in a missense amino acid change from tyrosine to cysteine; This variant is heterozygous; This gene is associated with both recessive and dominant disease; however, the dominant association to CMT is not well established (PanelApp, OMIM); Variant is located in the annotated alpha-N-acetylglucosaminidase (NAGLU) tim-barrel domain (DECIPHER); Loss of function is a known mechanism of disease in this gene and is associated with Mucopolysaccharidosis type IIIB (Sanfilippo B) (MIM#252920). The mechanism for Charcot-Marie-Tooth disease, axonal, type 2V (CMT; MIM#616491) is unclear; This variant has been shown to be maternally inherited (by trio analysis).
not provided Pathogenic:1
Published functional studies demonstrate significantly reduced enzyme activity (Beesley et al., 2005); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 16151907, 33763395, 30070758)
Mucopolysaccharidosis, MPS-III-B;C5569050:Charcot-Marie-Tooth disease axonal type 2V Pathogenic:1
This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 335 of the NAGLU protein (p.Tyr335Cys). This variant is present in population databases (rs768918822, gnomAD 0.004%). This missense change has been observed in individual(s) with NAGLU-related conditions (PMID: 16151907, 30070758, 33763395). ClinVar contains an entry for this variant (Variation ID: 557047). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on NAGLU protein function. Experimental studies have shown that this missense change affects NAGLU function (PMID: 16151907). This variant disrupts the p.Tyr335 amino acid residue in NAGLU. Other variant(s) that disrupt this residue have been determined to be pathogenic (internal data). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at